Eli Lilly and Co. is seeking emergency use authorization from the U.S. health regulator for the company’s experimental Covid-19 antibody monotherapy and plans to pursue a similar approval for a combination therapy with two of its antibody drugs in November 2020.
President Donald Trump was treated with an experimental antibody cocktail for Covid-19 and moved to a military hospital as a precautionary measure, White House officials said.
T cell shortage linked to severe Covid-19 in elderly; antiseptic spray may limit virus spread
Antibodies, Antiseptics, COVID-19 Antibodies, Doctors, Elderly, Immune Response, Immunoglobulin G (IgG), Infected Cells, Infected Cells, Inflammation, JAMA Otolaryngology Head and Neck Surgery, R&D, Scientists, Severe Covid-19, Studies, T-CellsA lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.
Eli Lilly and Co. has partnered with Amgen Inc. to increase the supply of the Indianapolis-based company’s experimental Covid-19 antibody treatments, a day after one of the drugs was shown to reduce the need for hospitalization.
Eli Lilly announced interim proof-of-concept data from the company’s BLAZE-1 Phase II clinical trial of LY-COV555, a neutralizing antibody therapy for Covid-19.